Drug Profile
Research programme: diabetes/obesity therapy - Neurelis
Latest Information Update: 04 Feb 2019
Price :
$50
*
At a glance
- Originator Albany Medical College
- Developer Aegis Therapeutics
- Class Peptides
- Mechanism of Action Leptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (Intranasal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO, Pill)
- 14 May 2010 Preclinical trials in Obesity in USA (Intranasal)